Reuters has reported that Britain on Friday asked its medicine regulator to assess Oxford University and AstraZeneca's AZN.L COVID-19 vaccine candidate for temporary supply, a step towards beginning a roll-out before the end of the year.
''AstraZeneca expects 4 million doses to be available in Britain by the end of next month, and health minister Hancock is targeting the roll-out to begin before Christmas,'' Reuters wrote.
"We have formally asked the regulator to assess the Oxford/AstraZeneca vaccine, to understand the data and determine whether it meets rigorous safety standards," Hancock said in a statement, reported by Reuters.
"This letter is an important step towards deploying a vaccine as quickly as safely possible."
More key notes
''Britain's Medicines and Healthcare products Regulatory Agency (MHRA) is already assessing the vaccine in a "rolling review" as data comes in on safety and efficacy.''
''Hancock has also asked the MHRA to approve the Pfizer/BioNTech candidate after it was shown to be 95% effective.''
''Oxford and AstraZeneca AZN.L published interim efficacy results on Monday, which showed that the vaccine could be 90% effective when given as a half dose followed by a full dose.''
''Questions have been raised about the Oxford/AstraZeneca data and the robustness of that result, though the MHRA approved the use of the half-dose/full-dose regime a subgroup received in the trial.''
''Britain's top science adviser said on Thursday that the interim results showed the Oxford/AstraZeneca vaccine worked.''
The pound is already solid on the prospects of a Brexit breakthrough and a faster economic recovery pertaining to a vaccine.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.